Eileen E Birch1, Jane C Khoury2, Carol Lynn Berseth3, Yolanda S Castañeda4, Jill M Couch5, Judy Bean2, Robert Tamer2, Cheryl L Harris3, Susan Hazels Mitmesser6, Deolinda M Scalabrin3. 1. Retina Foundation of the Southwest, Dallas, TX; Department of Ophthalmology, University of Texas Southwestern Medical Center, Dallas, TX. 2. Division of Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH. 3. Clinical Research, Department of Medical Affairs, Mead Johnson Nutrition, Evansville, IN. 4. Retina Foundation of the Southwest, Dallas, TX. 5. Department of Ophthalmology, University of Texas Southwestern Medical Center, Dallas, TX. 6. Clinical Research, Department of Medical Affairs, Mead Johnson Nutrition, Evansville, IN. Electronic address: susan.mitmesser@mjn.com.
Abstract
OBJECTIVE: To investigate the incidence of allergic and respiratory diseases through age 3 years in children fed docosahexaenoic acid (DHA)- and arachidonic acid (ARA)-supplemented formula during infancy. STUDY DESIGN:Children who completed randomized, double-blind studies of DHA/ARA-supplemented (0.32%-0.36%/0.64%-0.72% of total fatty acids, respectively) versus nonsupplemented (control) formulas, fed during the first year of life, were eligible. Blinded study nurses reviewed medical charts for upper respiratory infection (URI), wheezing, asthma, bronchiolitis, bronchitis, allergic rhinitis, allergic conjunctivitis, otitis media, sinusitis, atopic dermatitis (AD), and urticaria. RESULTS:From the 2 original cohorts, 89/179 children participated; 38/89 were fed DHA/ARA formula. The DHA/ARA group had significantly lower odds for developing URI (odds ratio [OR], 0.22; 95% confidence interval [CI], 0.08-0.58), wheezing/asthma (OR, 0.32; 95% CI, 0.11-0.97), wheezing/asthma/AD (OR, 0.25; 95% CI, 0.09-0.67), or any allergy (OR, 0.28; 95% CI, 0.10-0.72). The control group had significantly shorter time to first diagnosis of URI (P = .006), wheezing/asthma (P = .03), or any allergy (P = .006). CONCLUSIONS:DHA/ARA supplementation was associated with delayed onset and reduced incidence of URIs and common allergic diseases up to 3 years of age. Copyright 2010 Mosby, Inc. All rights reserved.
RCT Entities:
OBJECTIVE: To investigate the incidence of allergic and respiratory diseases through age 3 years in children fed docosahexaenoic acid (DHA)- and arachidonic acid (ARA)-supplemented formula during infancy. STUDY DESIGN:Children who completed randomized, double-blind studies of DHA/ARA-supplemented (0.32%-0.36%/0.64%-0.72% of total fatty acids, respectively) versus nonsupplemented (control) formulas, fed during the first year of life, were eligible. Blinded study nurses reviewed medical charts for upper respiratory infection (URI), wheezing, asthma, bronchiolitis, bronchitis, allergic rhinitis, allergic conjunctivitis, otitis media, sinusitis, atopic dermatitis (AD), and urticaria. RESULTS: From the 2 original cohorts, 89/179 children participated; 38/89 were fed DHA/ARA formula. The DHA/ARA group had significantly lower odds for developing URI (odds ratio [OR], 0.22; 95% confidence interval [CI], 0.08-0.58), wheezing/asthma (OR, 0.32; 95% CI, 0.11-0.97), wheezing/asthma/AD (OR, 0.25; 95% CI, 0.09-0.67), or any allergy (OR, 0.28; 95% CI, 0.10-0.72). The control group had significantly shorter time to first diagnosis of URI (P = .006), wheezing/asthma (P = .03), or any allergy (P = .006). CONCLUSIONS:DHA/ARA supplementation was associated with delayed onset and reduced incidence of URIs and common allergic diseases up to 3 years of age. Copyright 2010 Mosby, Inc. All rights reserved.
Authors: Kathleen Lee-Sarwar; Rachel S Kelly; Jessica Lasky-Su; Priyadarshini Kachroo; Robert S Zeiger; George T O'Connor; Megan T Sandel; Leonard B Bacharier; Avraham Beigelman; Nancy Laranjo; Diane R Gold; Scott T Weiss; Augusto A Litonjua Journal: J Allergy Clin Immunol Pract Date: 2018-08-24
Authors: Amanda M Foiles; Elizabeth H Kerling; Jo A Wick; Deolinda M F Scalabrin; John Colombo; Susan E Carlson Journal: Pediatr Allergy Immunol Date: 2016-01-21 Impact factor: 6.377